Liminatus Pharma, Inc. (Nasdaq: Limn) 与 Capital Trust Group 签署3000万美元权益投资谅解备忘录,采用盈余转化机制并探讨未来战略合作

美股速递
Oct 30, 2025

Liminatus Pharma, Inc. (Nasdaq: Limn) 与 Capital Trust Group 签署了一项谅解备忘录,以通过盈余转化机制进行3000万美元的权益投资,并探讨未来的战略合作。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10